Loading...
Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues
Galuska, S.P. Ward, S. Falconer, Robert A.
Galuska, S.P.
Ward, S.
Falconer, Robert A.
Publication Date
2023-10
End of Embargo
Supervisor
Rights
© 2023 The Authors. Published by Cell Press. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2023-10-12
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Harnessing the differences between cancer and non-cancer tissues presents new opportunities for selective targeting by anti-cancer drugs. CD13, a heavily glycosylated protein, is one example with significant unmetclinical potential in cancer drug discovery. Despite its high expression and activity in cancers, CD13 is also expressed in many normal tissues. Here, we report differential tissue glycosylation of CD13 across tissues and demonstrate for the first time that the nature and pattern of glycosylation of CD13 in preclinical cancer tissues are distinct compared to normal tissues. We identify cancer-specific O-glycosylation of CD13, which selectively blocks its detection in cancer models but not in normal tissues. In addition, the metabolism activity of cancer-expressed CD13 was observed to be critically dependent on its unique glycosylation. Thus, our data demonstrate the existence of discrete cancer-specific CD13 glycoforms and propose cancer-specific CD13 glycoforms as a clinically useful target for effective cancer-targeted therapy.
Version
Published version
Citation
Mprah Barnieh F, Galuska SP, Loadman P et al (2023) Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues. iScience. 26: 108219
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article